PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Stock Information for Epizyme Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Epizyme Inc.

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ("FDA")
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1-19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.